FDA Diagnostics Chief Predicts Multiple Warning Letters For ASR Violations
This article was originally published in The Gray Sheet
Executive Summary
FDA expects to send out multiple warning letters to firms for illegally selling diagnostic products as 510(k)-exempt analyte specific reagents instead of as test kits, which are more heavily regulated